-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Product Theaters

Saturday, December 7, 2024

Saturday | Sunday | Monday | top

11:30 AM-12:30 PM

A New Treatment Strategy in cGVHD
Beyond the Data: Long-Term Efficacy & Safety Integrated Analyses and a Patient's Journey with Paroxysmal Nocturnal Hemoglobinuria (PNH)
CAR T Cell Therapy for Second-line (2L) LBCL
Choosing a Different Approach: Clinical and Nonclinical Factors for Adults with PNH on FABHALTA
Getting Started and Transitioning to Outpatient Care for Patients With Relapsed or Refractory Multiple Myeloma
Learn about an alternative treatment for certain B-cell malignancies. This program is sponsored by Lilly USA, LLC.
Learn About Time Off Treatment with a BCL-2 Inhibitor-based Regimen for CLL/SLL

Sunday, December 8, 2024

Saturday | Sunday | Monday | top

8:00 AM-9:00 AM

Options When a Matched Allogeneic-HCT Source is Not Available
Redefining Frontline Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
The Science Behind HYMPAVZI (Marstacimab-hncq): Introducing an Innovative Treatment Option from Pfizer
Transforming aTTP/iTTP Treatment and Management
Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+ FL

11:30 AM-12:30 PM

Addressing Critical Unmet Needs With Newly Diagnosed Ph+CML-CP
A First-Line Treatment Option for Adults with Symptomatic Anemia Due To Lower-Risk MDS
Discover Gene Therapy as a Treatment Option for Hemophilia B
Discover the exciting details about a BCMA Bispecific for 4L+ RRMM

Monday, December 9, 2024

Saturday | Sunday | Monday | top

8:00 AM-9:00 AM

A first-in-class treatment for RRMM patients

12:15 PM-1:15 PM

A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS
What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma?